These previous observations are in agreement with our study, in which topical application of Ac-RLYE, a VEGFR-2 antagonist, alleviated inflammatory phenotypes and AD-like symptoms in HDM-challenged mice. This evidence concerns the gene KDR and Alzheimer disease.